Moderna's Nasdaq-100 Return Adds a Second Engine, but Bank of America Keeps the Brakes On

Moderna's re-entry into the Nasdaq-100 on October 9 gives the stock a fresh source of demand that has nothing to do with its science. The index slot, vacated by Warner Bros. Discovery, could pull in buying from passive funds and sharpen attention on the shares, according to media reports. It is a mechanical tailwind — one that sits alongside, not on top of, the clinical story that has driven the stock's recent swings.

That distinction matters more than usual right now. The same day the index news circulated, Bank of America lifted its price target on Moderna from $200 to $220 while leaving its rating at "Neutral." A higher target paired with an unchanged verdict is a cautious re-rating, not a ringing endorsement. Anyone reading the target alone is missing half the message.

Two Catalysts That Don't Talk to Each Other

Index-linked purchases say nothing about whether intismeran autogene, the therapy Moderna is developing with Merck, actually works. By the same token, the passive-fund demand doesn't hinge on whether trial results clear the bar Wall Street has set. The two threads run in parallel and should be judged separately.

Bank of America's stance, as reported by Reuters, is that the positive study data investors are waiting for is already baked into the share price. That is why the target went up without the rating following. The analysts are focused on the size of the clinical benefit and whether it holds consistently across disease stages — a positive headline result on its own won't settle those questions.

Jefferies offers a different lens, projecting peak sales of more than $3 billion for the therapy in melanoma alone. That figure is an estimate, not revenue already booked.

What the Calendar Actually Delivers

The full results from the INTerpath-001 trial are due on October 24 at the ESMO congress. The study compares intismeran autogene plus Keytruda against Keytruda alone in patients with surgically removed high-risk melanoma, across 1,137 patients with stage IIB to IV disease. Moderna and Merck flagged positive results on August 19; the detailed presentation is still to come. Moderna has also scheduled an investor call for the same afternoon.

A date on the calendar explains the attention but doesn't prejudge the outcome. Neither the direction of the data nor its commercial weight can be read off an announced presentation. Investors positioning ahead of the readout — which media reports identified as the main force behind a 4.6% gain in the prior session, with the analyst move playing a supporting role — are betting on an event, not reacting to one.

A second checkpoint follows on November 6, when Moderna plans to report third-quarter 2026 results alongside a business overview.

The Read-Through

The stock's recent advance is understandable as a build-up of expectations. It is not confirmation of them. The unchanged Neutral rating is the reminder here: a raised target and a higher conviction level are not the same thing. The heavier lifting has to come from the company's own announcements — the melanoma data first, then the quarterly update — rather than from the price action that runs ahead of them.